发布求助
文献互助 智能选刊 最新文献

Japanese Journal of Cancer and Chemotherapy最新文献

筛选
英文 中文
[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab]. 一种新的胃癌分子靶向药物——抗claudin 18.2抗体，Zolbetuximab。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Kazumasa Yamamoto, Izuma Nakayama, Kohei Shitara
{"title":"[A New Molecular Targeted Agent for Gastric Cancer-The Anti-Claudin 18.2 Antibody, Zolbetuximab].","authors":"Kazumasa Yamamoto, Izuma Nakayama, Kohei Shitara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The standard first-line treatment for unresectable advanced or recurrent gastric cancer(GC)and gastroesophageal junction cancer(GEJC)has been a platinum doublet chemotherapy. Trastuzumab with chemotherapy is the standard regimen for HER2-positive GC/GEJC. While, for HER2-negative cases, chemotherapy with or without immune checkpoint inhibitors (ICIs)such as nivolumab or pembrolizumab are regarded as the standard therapy. However, many patients do not derive benefit from anti-HER2 targeted therapies or ICIs, and new therapeutic targets have been explored. CLDN18.2 has emerged as a tissue-specific therapeutic target in gastric cancer. Zolbetuximab, a first-in-class chimeric IgG1 monoclonal antibody targeting CLDN18.2, has been developed. Zolbetuximab induces cancer cell death through antibody-dependent cellular cytotoxicity(ADCC)and complement-dependent cytotoxicity(CDC). Recently, zolbetuximab with chemotherapy improved survival rates in HER2-negative CLDN18.2-positive previously untreated patients with unresectable advanced or recurrent GC/GEJC, leading to its approval in Japan and its establishment as a standard treatment. GC/GEJC with early onset, scirrhous type or peritoneum dissemination commonly express CLDN18.2. The emergence of this novel therapeutic option is of great significance in clinical practice. We will highlight the previous clinical trials of zolbetuximab and provide future perspective of CLDN18.2 targeted therapy. In addition, we will introduce the ongoing development of various CLDN18.2 targeting therapies such as newer monoclonal antibodies, antibody-drug conjugates(ADCs), chimeric antigen receptor T-cell(CAR- T)therapy, and bispecific antibodies.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1111-1118"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cancer Malignancy by Abnormal Claudin Expression]. [Claudin异常表达引起的恶性肿瘤]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Yuta Yoshino, Akira Ikari
{"title":"[Cancer Malignancy by Abnormal Claudin Expression].","authors":"Yuta Yoshino, Akira Ikari","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An elevated expression of claudins(CLDNs), tight junctional proteins, are reported in various solid tumors. However, the expression mechanisms and pathophysiological roles of CLDNs have not been well clarified. So far, we found that CLDN2 and CLDN14 are highly expressed in lung adenocarcinoma and colorectal cancer cells, respectively. These CLDNs augmented proliferation of cancer cells. Furthermore, these CLDNs enhanced chemoresistance of cancer spheroids mediated by the elevation of oxidative stress and activation of Nrf2 signal pathway. The restriction of glucose supply, shift of glucose metabolism from aerobic glycolysis towards oxidative phosphorylation, and elevation of mitochondria activity were suggested to be involved in the CLDN2-dependent activation of Nrf2 signal pathway. The CLDN expression inhibitors are expected to have functions of proliferation inhibition and anticancer drug resistance improvement effects. We have to search for the optimal CLDN subtype as therapeutic target because the expression pattern of CLDN subtypes is different in the type of cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1100-1104"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Case of Long-Term Survival after Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma]. [无法切除的局部晚期食管鳞状细胞癌化疗后长期存活病例］
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Satoru Matono, Takafumi Ohchi, Sho Setojima, Atsushi Kaibara, Naoki Mori, Kohei Saisho, Masashi Nakagawa, Haruhiro Hino, Nobuya Ishibashi, Toshiaki Tanaka, Fumihiko Fujita, Etsuyo Ogo
{"title":"[Case of Long-Term Survival after Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma].","authors":"Satoru Matono, Takafumi Ohchi, Sho Setojima, Atsushi Kaibara, Naoki Mori, Kohei Saisho, Masashi Nakagawa, Haruhiro Hino, Nobuya Ishibashi, Toshiaki Tanaka, Fumihiko Fujita, Etsuyo Ogo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>67-year-old woman underwent definitive chemoradiotherapy( dCRT) with cisplatin( CDDP) and 5-fluorouraci(l 5-FU)(FP) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus. During treatment, the patient developed grade 3 pharyngitis and esophagitis as adverse events. She was administered maintenance chemotherapy with 2 courses of FP and achieved complete response. Currently, she experiences esophageal stenosis; however, she remains alive and recurrence-free 9 years after initial treatment. While dCRT is effective for locally advanced esophageal cancer, its adverse effects may persist. Herein, we report our case and have included relevant literature considerations.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1161-1164"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Locally Advanced Breast Cancer with Ulceration, in Which the Combination of Mohs' Paste and Systemic Drug Therapy Resulted in Improvement of Quality of Life and Disease Control]. 【局部晚期乳腺癌合并溃疡1例莫氏膏联合全身药物治疗改善患者生活质量及疾病控制】。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Takeshi Hashimoto, Kazuhiko Tsuchiya, Yoko Sakoda, Mitsutoshi Ogino
{"title":"[A Case of Locally Advanced Breast Cancer with Ulceration, in Which the Combination of Mohs' Paste and Systemic Drug Therapy Resulted in Improvement of Quality of Life and Disease Control].","authors":"Takeshi Hashimoto, Kazuhiko Tsuchiya, Yoko Sakoda, Mitsutoshi Ogino","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Locally advanced breast cancer can lead to self-destruction, necrosis, and malodor, which may reduce the patients' quality of life. We encountered a case where the combination of Mohs' paste and systemic drug therapy for locally advanced breast cancer improved quality of life and achieved marked disease control. The patient, a woman in her 70s, was referred to our department with suspected right breast cancer. After thorough examination, she was diagnosed with cT4bN3aM1(PUL), cStage Ⅳ, invasive ductal carcinoma, HER2 type. Mohs' paste treatment began on the 8th day, and systemic drug therapy was initiated on the 22nd day. Mohs' paste was applied once a week for a total of 4 times, resulting in significant tumor shrinkage. More than 6 months have passed since the start of treatment, and a complete response has been maintained, including pulmonary metastasis. Mohs' paste is a useful treatment for locally advanced breast cancer with self-destruction and necrosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1153-1155"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ⅳ. Perioperative Treatment Strategy for Colorectal Liver Metastases]. Ⅳ。结直肠癌肝转移的围手术期治疗策略[j]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Kay Uehara, Takeshi Yamada, Seiichi Shinji, Akihisa Matsuda, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Hiroshi Yoshida
{"title":"[Ⅳ. Perioperative Treatment Strategy for Colorectal Liver Metastases].","authors":"Kay Uehara, Takeshi Yamada, Seiichi Shinji, Akihisa Matsuda, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Hiroshi Yoshida","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1134-1137"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Advanced Gastric Cancer with Radical Para-Aortic Lymph Node Dissection Following Gastric-Jejunal Bypass for Pyloric Stenosis and Preoperative Chemotherapy]. [晚期胃癌胃空肠分流术治疗幽门狭窄及术前化疗伴根治性主动脉旁淋巴结清扫1例]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Ryosuke Mizuno, Sanae Nakajima
{"title":"[A Case of Advanced Gastric Cancer with Radical Para-Aortic Lymph Node Dissection Following Gastric-Jejunal Bypass for Pyloric Stenosis and Preoperative Chemotherapy].","authors":"Ryosuke Mizuno, Sanae Nakajima","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a man in his 60s who complained of gastric reflux and was diagnosed with advanced gastric cancer (tub1, por1)involving pyloric stenosis. Computed tomography revealed an enlarged para-aortic lymph node(PALN, #16a2). His preoperative diagnosis was cT4aN2M1(LYM), cStage Ⅳb. The patient underwent laparoscopic gastric jejunal bypass surgery to treat the pyloric obstruction and was administered 2 courses of preoperative chemotherapy with S-1+L-OHP(SOX). Significant shrinkage was observed in both the primary tumor and surrounding lymph node metastases, and the PALN did not exhibit further enlargement. Therefore, the patient was eligible for surgery. Intraoperative diagnosis of PALN#16a2 was positive for metastasis, and distal gastrectomy with radical para-aorticlymph node dissection(#16a2+b1)was performed. The gastric jejunal bypass was preserved for reconstruction, and the pathological diagnosis was ypT2N3(15/60). Following discharge, adjuvant chemotherapy with S-1+DTX(DS)was performed for 1 year, and no recurrence has been observed for 1 year and 6 months. This study showed that advanced gastric cancer with pyloric stenosis and PALN enlargement can be treated with radical para-aortic lymph node dissection through prompt introduction of preoperative chemotherapy following gastric jejunostomy bypass surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1169-1171"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Epigenome Diagnosis of Cancer-Focusing on Genome-Wide DNA Methylation Diagnosis of Colorectal Cancer for Predicting Sensitivity of Anti-EGFR Antibody Treatment]. [癌症的表观基因组诊断——关注结直肠癌全基因组DNA甲基化诊断预测抗egfr抗体治疗敏感性]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Chikashi Ishioka, Kota Ouchi, Shonosuke Wakayama, Shin Takahashi
{"title":"[Epigenome Diagnosis of Cancer-Focusing on Genome-Wide DNA Methylation Diagnosis of Colorectal Cancer for Predicting Sensitivity of Anti-EGFR Antibody Treatment].","authors":"Chikashi Ishioka, Kota Ouchi, Shonosuke Wakayama, Shin Takahashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Epigenetic regulation mechanisms such as DNA methylation and histone acetylation are important for controlling various biological phenomena by regulating gene expression at the genome level. They are reversible systems that change depending on environmental factors. Epigenetic abnormalities are associated with the onset of various diseases, including developmental and aging abnormalities, neurological disorders, and malignant tumors. Aberrant DNA methylation is an important epigenetic change in the development and progression of colorectal cancer. DNA methylation in tumor tissues occurs mainly in CpG islands in the promoter regions of genes and inactivates gene functions by negatively suppressing transcription. CpG island methylator phenotype(CIMP)is an important carcinogenic mechanism of colorectal cancer related to DNA methylation and is involved in approximately 20% of all colorectal cancers. CIMP is generally judged to be positive when a certain percentage or more of the marker gene set is methylated, and many CIMP markers have been reported so far. However, no established marker has been set to classify colorectal cancer by genome-wide DNA methylation. We developed a new method to assess genome-wide DNA methylation status and obtained pharmaceutical approval as a new in vitro diagnostic drug to predict sensitivity to anti-EGFR antibody drugs in colorectal cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1089-1094"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ⅲ. Preoperative Treatment for Locally Advanced Rectal Cancer]. Ⅲ。局部晚期直肠癌的术前治疗[j]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Shigenobu Emoto, Soichiro Ishihara
{"title":"[Ⅲ. Preoperative Treatment for Locally Advanced Rectal Cancer].","authors":"Shigenobu Emoto, Soichiro Ishihara","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1129-1133"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Lower G. I. /Colon and Rectum Cancer Changes in the Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2024 for the Treatment of Colorectal Cancer]. [Lower g.i. /日本结直肠癌协会（JSCCR） 2024年结直肠癌治疗指南中结肠和直肠癌症的变化]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-11-01
Kei Muro
{"title":"[Lower G. I. /Colon and Rectum Cancer Changes in the Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2024 for the Treatment of Colorectal Cancer].","authors":"Kei Muro","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 11","pages":"1119"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Combined Efficacy of Dendritic Cell Vaccine and Oncolytic Adenovirus in Colorectal Cancer]. [树突状细胞疫苗和溶瘤腺病毒对结直肠癌的联合疗效]。
Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-10-01
Naohiro Okada, Hiroshi Tazawa, Motohiko Yamada, Kanto Suemori, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara
{"title":"[Combined Efficacy of Dendritic Cell Vaccine and Oncolytic Adenovirus in Colorectal Cancer].","authors":"Naohiro Okada, Hiroshi Tazawa, Motohiko Yamada, Kanto Suemori, Satoru Kikuchi, Shinji Kuroda, Kazuhiro Noma, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Dendritic cell(DC)vaccine therapy has been widely studied as cancer immunotherapy that potently induces cytotoxic T lymphocytes. However, their efficacy in clinical practice has not yet been established. We have developed an oncolytic adenovirus OBP-702 carrying the tumor suppressor gene p53 and have demonstrated its therapeutic potential to induce cytopathic effect and activate antitumor immunity via p53 induction. In this study, we investigated the combined effect of p53-transduced DC vaccine and OBP-702 in colorectal cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 10","pages":"1035-1037"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信